Snibe Brand Guidelines: Shenzhen’s 1995 Lab Maker Behind the MAGLUMI Analysers

A Shenzhen company from 1995.

Snibe is the short name of Shenzhen New Industries Biomedical Engineering Co., Ltd., a maker of laboratory instruments and the reagents that run on them. The company says it was founded in December 1995 and is located in the National Biological Industry Park in Shenzhen, in southern China. It describes itself as “a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents,” organised around three centres: reagent research and production, instrument research and production, and sales and marketing.

The company’s own milestone list sets out its early years. In 1997, it says, it developed an enzyme-linked immunoassay system called Magimuzyme. In 2002 it received a “Shenzhen High-tech Enterprise” award, and in 2005 it developed a semi-automatic analyser for chemiluminescence immunoassay, or CLIA, with dedicated reagent kits, and received a Shenzhen science and technology progress award. In 2007, the company says, it was certified to ISO 9001 and ISO 13485 by TÜV.

CLIA became the centre of the business. Snibe says that in 2008 it developed “China’s first automated CLIA analyzer” and dedicated kits, launching the automated analyser in 2010. It dates its first integrated system to 2012, which it also describes as a first for China, and a high-throughput CLIA analyser to 2013. Its website title still leads with the method — “CLIA products” — and a test menu of “up to 278 parameters.”

The firm also moved premises as it grew. Its timeline records a new production centre and headquarters put into use in 2014, construction of a new headquarters in Pingshan, in the east of Shenzhen, beginning in 2015, and that headquarters coming into use in 2019.

MAGLUMI and the FDA.

The name most associated with Snibe’s analysers is MAGLUMI. Its independent paper trail begins in the United States. The FDA’s public 510(k) database records a clearance dated 14 July 2017 for the MAGLUMI 2000 TSH assay and the MAGLUMI 2000 immunoassay analyser, filed by Shenzhen New Industries Biomedical Engineering. The company says that made it the first CLIA manufacturer in China to be cleared by the FDA.

Further US clearances followed in the same database: a MAGLUMI 2000 FT4 assay in 2018, a 25-OH vitamin D assay in 2019, an HCG/β-HCG assay in January 2020 and, in April 2024, the MAGLUMI X3 fully automatic analyser with a 25-OH vitamin D assay.

At home, Snibe says it was listed on the Shenzhen Stock Exchange in 2020. The years since have widened the range. The company dates the launch of molecular diagnostics and point-of-care testing to 2021, and says that in 2022 it became the first Chinese CLIA manufacturer with CE List A marking for its HBV, HCV and HIV assays. In 2023, it says, it became a stakeholder member of the JCTLM, the international committee on traceability in laboratory medicine, and in 2024 its new operations centre was topped out.

Its 2025 launches, by its own account, were the MAGLUMI X10 immunoassay analyser, the Biossays C10 biochemistry analyser and the Hemolumi H6, the first product of a new haemostasis line. The current MAGLUMI family on its website runs from the X3 through the X6 and X8 to the X10.

The product families now carry distinct names: MAGLUMI for immunoassay, Biossays for biochemistry and electrolytes, Molecision for molecular analysers and Hemolumi for coagulation. Three of the names, with the combined Biolumi system, share the syllable “lumi.”

Design and documentation.

In vitro diagnostics is a business most people meet only at second hand, through a blood sample sent away or a result read back by a doctor. The companies behind those results make analysers, the reagents that run on them and the software that ties them together, and they sell mainly to hospital laboratories, independent labs and clinics rather than to the public.

That shapes how they look. The typical product photograph shows a white or pale grey bench analyser in a clean laboratory, sometimes linked to others in a line of automation, with sample tubes standing in racks and a touchscreen at the front. Smaller formats appear too: single-use cartridges for point-of-care machines, test strips and cassettes for rapid tests, pipettes and reagent packs. Blue and white palettes are common across the sector, along with plain sans serif type and diagrams of the laboratory workflow, and some makers have had their instruments judged on design: Sysmex’s clinical laboratory system was among the Good Design Gold Award winners in Japan in 2011.

The trade meets at a few large events. MEDICA in Düsseldorf gathers medical technology makers, and the annual meeting of ADLM, the Association for Diagnostics & Laboratory Medicine, formerly the American Association for Clinical Chemistry, brings laboratory companies together in the United States. Some of these groups grew by acquisition, so a single corporate name often sits above product names that began with other companies.

This guide sets out what can be checked about each brand: who founded it, who owns it, where its products are made and what it says about its own identity, and it marks clearly what rests only on the company’s own word. No diagnostic or clinical claims are made for any product.

A brand built on trade fairs and analysers.

Snibe presents itself to laboratories largely through the international trade-fair circuit. Its own news pages report that at MEDICA 2025, held at Messe Düsseldorf from 17 to 20 November 2025, it headlined the MAGLUMI X10 and the Hemolumi H6. At ADLM 2026 in Anaheim, California, LabMedica reported on 30 July 2026, the company showed the SATLARS mini-T8, which the magazine described as the newest member of its Total Laboratory Automation Solutions, designed for laboratories with limited space.

The same report described the Biolumi CX Solution-X10+C10, which combines the MAGLUMI X10 immunoassay analyser with the Biossays C10 biochemistry analyser so that immunoassay, biochemical and electrolyte tests can run from one sample loading. LabMedica also noted the MAGLUMI X8 as a system designed for medium- to large-volume laboratories.

The name is written two ways. The company’s about page and its website title use “Snibe” and “Snibe Diagnostic,” while LabMedica’s 2026 report and some of the company’s own event pages set it in capitals as “SNIBE.” The longer legal name, Shenzhen New Industries Biomedical Engineering, appears in the website’s copyright line and in the FDA’s records.

Its website is published in English, Chinese, French, Portuguese, Russian and Spanish, and its qualification page lists certificates and memberships including ISO 13485, the EU’s IVDR CE marking and membership of the IFCC, the international federation of clinical chemistry. The company’s stated mission is “creating value for human health through continuous innovation,” and its motto is “Quality is Our Life.”

For a design guide, Snibe shows how a laboratory maker can build a family of product names around one root syllable and one testing method. Compare DiaSorin, another maker of chemiluminescence immunoassay systems, and Wondfo, a Chinese diagnostics maker from Guangzhou. For this guide we use a deep teal, a pale mist and a soft sea green with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Snibe’s identity on hand — save it to a board in the Made Good inspiration library.